English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Tuberculosis (TB) is one of the top ten causes of death worldwide, with approximately 10.0 million active TB cases in 2017 (range 9.0 to 11.1 million) occurring in all countries and age groups and estimates of 1.7 billion people having latent TB infection (LTBI). The lifetime risk for reactivation of LTBI is 5% to10%, and certain immunosuppressant therapies increase this risk. Data on TB risk following anti-interleukin (IL)-17A treatment in humans are limited, with no cases of LTBI reactivation reported thus far. This article is protected by copyright. All rights reserved.

british journal of dermatology

Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis